Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194570 · ClinicalTrials.gov registry record · Phase 3
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 735
- Enrollment target
NCT01194570 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 735 participants.
The verdict
NCT01194570, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 735 participants
- Enrollment target
Study Summary
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.
Interventions
- OTHER Placebo
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2011-03-02 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194570
The ClinicalTrials.gov registry entry for NCT01194570 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 735 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01194570 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194570 about?
NCT01194570 is a clinical study titled "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis". This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. Eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.
What is the current status of trial NCT01194570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 735 participants. The study started on 2011-03-02. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT01194570?
The interventions under investigation include: Placebo (OTHER), Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT01194570?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.